Sign Out
Sacubitril-valsartan (Vymada) is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
Clinical judgement should be used in deciding whom to treat as LVEF is a variable measure.
Sacubitril-valsartan (Vymada) is administered in place of an ACE inhibitor or ARB.
Continue with Google